Stocks & Investing
Stocks and Investing
Stocks and Investing
Wed, October 23, 2019
[ Wed, Oct 23rd 2019
] - WOPRAI
[ Wed, Oct 23rd 2019
] - WOPRAI
[ Wed, Oct 23rd 2019
] - WOPRAI
[ Wed, Oct 23rd 2019
] - WOPRAI
[ Wed, Oct 23rd 2019
] - WOPRAI
[ Wed, Oct 23rd 2019
] - WOPRAI
Tue, October 22, 2019
[ Tue, Oct 22nd 2019
] - WOPRAI
[ Tue, Oct 22nd 2019
] - WOPRAI
[ Tue, Oct 22nd 2019
] - WOPRAI
[ Tue, Oct 22nd 2019
] - WOPRAI
[ Tue, Oct 22nd 2019
] - WOPRAI
[ Tue, Oct 22nd 2019
] - WOPRAI
[ Tue, Oct 22nd 2019
] - WOPRAI
[ Tue, Oct 22nd 2019
] - WOPRAI
[ Tue, Oct 22nd 2019
] - WOPRAI
[ Tue, Oct 22nd 2019
] - WOPRAI
[ Tue, Oct 22nd 2019
] - WOPRAI
[ Tue, Oct 22nd 2019
] - WOPRAI
[ Tue, Oct 22nd 2019
] - WOPRAI
[ Tue, Oct 22nd 2019
] - WOPRAI
[ Tue, Oct 22nd 2019
] - WOPRAI
[ Tue, Oct 22nd 2019
] - WOPRAI
[ Tue, Oct 22nd 2019
] - WOPRAI
[ Tue, Oct 22nd 2019
] - WOPRAI
[ Tue, Oct 22nd 2019
] - WOPRAI
Robyn Karnauskas Maintained (VRTX) at Strong Buy with Increased Target to $225 on, Oct 22nd, 2019
Robyn Karnauskas of Citigroup, Maintained "Vertex Pharmaceuticals Incorporated" (VRTX) at Strong Buy with Increased Target from $205 to $225 on, Oct 22nd, 2019.
Robyn has made no other calls on VRTX in the last 4 months.
There are 6 other peers that have a rating on VRTX. Out of the 6 peers that are also analyzing VRTX, 1 agrees with Robyn's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Alan Carr of "Needham" Downgraded from Strong Buy to Hold on, Thursday, August 1st, 2019
These are the ratings of the 5 analyists that currently disagree with Robyn
- Ying Huang of "B of A Securities" Initiated at Strong Buy and Held Target at $220 on, Thursday, October 17th, 2019
- Matthew Harrison of "Morgan Stanley" Maintained at Buy with Increased Target to $240 on, Friday, September 6th, 2019
- Paul Matteis of "Stifel" Maintained at Strong Buy with Increased Target to $211 on, Thursday, August 1st, 2019
- Edward Tenthoff of "Piper Sandler" Maintained at Buy with Increased Target to $230 on, Thursday, August 1st, 2019
- Evan Seigerman of "Credit Suisse" Maintained at Buy with Increased Target to $213 on, Thursday, August 1st, 2019
